With full membership, watch our educational and editorial videos, search the site, receive our newsletters, join discussions, download slides and much more.
How do drug-eluting stents compare? Our panel of experts, Drs. Stone, Kereiakes, Serruys, and Windecker discuss the late-breaking trials at TCT 2009 of DES vs DES.
Recently published data suggest that prior polyvascular disease increases the risk for inhospital adverse events in patients with ACS. Join Drs. Deepak Bhatt, Jean-Pierre Bassand, and José R. Gonzalez-Juanatey for a discussion of the current data on identification and management of patients with polyvascular disease.
AF can lead to stroke, congestive heart failure, and other serious complications. Successful management should include reducing these risks. Join our expert panel, Drs. Peter Rothwell, Donald Easton, and Mark Alberts, as they discuss new data and strategies for improving outcomes in patients with AF.
Despite modern therapy, the rates of death, MI, bleeding, and readmission remain high in patients with ACS. Join Drs. Jeffery Popma, Héctor Bueno, Freek Verheugt, and Sunil. Rao for a review of the latest data on antiplatelet therapy for patients with ACS.
Variable rate contrast delivery systems have the potential to improve workflow and patient outcomes by providing a more precise flow of contrast. Watch Dr. Jeffrey Moses and his team as they demonstrate the use of the device in the cath lab in a patient with complex lesions.
Several recent studies have demonstrated that patients with atherothrombosis who experience bleeding may be at increased risk for long-term adverse ischemic events. Whereas the specific mechanism(s) that may explain the correlation between bleeding and ischemic events remains to be fully elucidated, these findings may have important ramifications for the selection of appropriate antiplatelet therapy. Drs. Berger, Mehta, Simon, Steg, and White discuss.
Harmonizing guideline recommendations for antiplatelet therapy with recent clinical trial data and concerns about bleeding can pose a challenge. Drs Berger, Mehta, Simon, Steg, and White each give presentations addressing issues relating to the appropriate use of antiplatelet therapy in patients with atherothrombotic disease
In our first program Drs Gibbons, Holmes, and Simari discuss cell therapy and the latest trials in intervention. Our second program features Drs Gibbons, Ackerman, and Redfield discuss personalized genomics and heart failure.
Warfarin remains the cornerstone of stroke prevention in patients with AF. However, many patients are unable or unwilling to take it. Could antiplatelet therapy fill this gap? How might investigational anticoagulants change the playing field? Dr Naccarelli leads a panel discussion with Drs Connolly and Camm.